Company Filing History:
1 out of 2 
1 out of 832,718 Years Active: 1996
Title: Ulf Norinder: Innovator in Receptor Ligands
Introduction
Ulf Norinder is a notable inventor based in Södertälje, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of receptor ligands. With a total of 2 patents, his work focuses on compounds that play a crucial role in therapeutic treatments.
Latest Patents
Norinder's latest patents include innovative compounds that serve as 3,5,3'-triiodothyronine (T-3) receptor ligands. These compounds are designed for the preparation of medicaments aimed at treating disorders dependent on the expression of T-3 regulated genes. The patents disclose various compounds, including 3,5-diiodo-4-(2-N,N-diethylaminoethoxy)phenyl-(2-butylbenzofur-3-yl)methanol hydrochloride and 2-methyl-3-(3,5-diiodo-4-(2-N,N-diethylaminoethoxy)-benzoyl)benzofuran hydrochloride, among others. Additionally, the invention outlines methods for prophylactically or therapeutically treating patients with such disorders.
Career Highlights
Throughout his career, Ulf Norinder has worked with various companies, including Karo Bio Aktiebolag. His expertise in receptor ligands has positioned him as a key figure in the pharmaceutical industry. His contributions have been instrumental in advancing the understanding and treatment of disorders related to T-3 regulated genes.
Collaborations
Norinder has collaborated with notable professionals in the field, including Jurgen Bajorath and Jay F Stearns. These collaborations have further enriched his research and development efforts, leading to innovative solutions in medicinal chemistry.
Conclusion
Ulf Norinder's work in receptor ligands exemplifies the impact of innovation in the pharmaceutical industry. His patents and collaborations highlight his commitment to advancing therapeutic treatments for complex disorders.